ReviewCurrent neurology and neuroscience reports2015
Vaccine therapies in malignant glioma.
Review in Current neurology and neuroscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis.Oncology reviews · 2024Pooled it
- Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026Review
- Natural Products for the Immunotherapy of Glioma.Nutrients · 2023Review
- Molecular targeted therapy: A new avenue in glioblastoma treatment.Oncology letters · 2023Review
- Review
- Current Immunotherapeutic Approaches for Malignant Gliomas.Brain tumor research and treatment · 2022Review
- Immunotherapy and radiation for high-grade glioma: a narrative review.Translational cancer research · 2021Review
- Review
- Lipid-Based Nanocarriers for The Treatment of Glioblastoma.Advanced nanobiomed research · 2021Article
- CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.Frontiers in neuroscience · 2021Review
- T lymphocyte-targeted immune checkpoint modulation in glioma.Journal for immunotherapy of cancer · 2020Review
- Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatmentTheranostics · 2020Review
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2019Article
- An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells.Cancer immunology, immunotherapy : CII · 2019Article
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2018Article
- Prospect of rindopepimut in the treatment of glioblastoma.Expert opinion on biological therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.